Analyzing JK06 Phase I/II Expansion Cohort Data: Leveraging Biparatopic & Conjugation Design to Unlock Novel Activity & Safety Profile - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Register by Friday, August 7 & Save up to $600

Day

Hour

Minute

Second

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Analyzing JK06 Phase I/II Expansion Cohort Data: Leveraging Biparatopic & Conjugation Design to Unlock Novel Activity & Safety Profile

12:00 pm - Wednesday 14th October 2026

Outlining the developing clinical profile of JK06 from dose escalation to Phase I/II expansion cohort data
Contextualizing the maturing clinical profile of JK06 across efficacy and safety profile in lung and breast cancer cohorts
Explaining the differentiated clinical impact of JK06 through dual epitope binding and site specific conjugation for a novel ADC activity and safety profile

Speakers:

Samuel Murphy

Samuel Murphy

Chief Executive Officer

Salubris Biotherapeutics Inc.